Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: An analysis of the phase 3 REACH study

Ian Chau, Joon Oh Park, Baek Yeol Ryoo, Chia Jui Yen, Ronnie Poon, Davide Pastorelli, Jean Frédéric Blanc, Masatoshi Kudo, Tulio Pfiffer, Etsuro Hatano, Hyun Cheol Chung, Katerina Kopeckova, Jean Marc Phelip, Giovanni Brandi, Shinichi Ohkawa, Chung Pin Li, Takuji Okusaka, Yanzhi Hsu, Paolo B. Abada, Andrew X. Zhu

研究成果: Article同行評審

11 引文 斯高帕斯(Scopus)

摘要

Background: Post-hoc analyses of AFP response and progression and their relationship with objective measures of response and survival were performed in patients from REACH. Methods: Serum AFP was measured at baseline and every 3 cycles (2 weeks/cycle). Associations between AFP and radiographic progression and efficacy end points were analysed. Results: Median percent AFP increase from baseline was smaller in the ramucirumab than in the placebo arm throughout treatment. Time to AFP progression (HR 0.621; P < 0.0001) and to radiographic progression (HR 0.613; P < 0.0001) favoured ramucirumab. Association between AFP and radiographic progression was shown at 6 (OR 6.44, 95% CI 4.03, 10.29; P < 0.0001) and 12 weeks (OR 2.28, 95% CI 1.47, 3.53; P = 0.0002). AFP response was higher with ramucirumab compared with placebo (P < 0.0001). More patients in the ramucirumab arm experienced tumour shrinkage and AFP response compared with placebo. Survival was longer in patients with AFP response (13.6 months) than in patients without (6.2 months), irrespective of treatment (HR 0.457, P < 0.0001). Conclusions: Treatment with ramucirumab prolonged time to AFP progression, slowed AFP increase and was more likely to induce AFP response. Similar benefits in radiographic progression and response correlated with AFP changes.

原文English
頁(從 - 到)19-26
頁數8
期刊British Journal of Cancer
119
發行號1
DOIs
出版狀態Published - 2018 七月 3

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

指紋 深入研究「Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: An analysis of the phase 3 REACH study」主題。共同形成了獨特的指紋。

引用此